Characterizing Health Outcomes in Idiopathic Pulmonary Fibrosis using US Health Claims Data

Respiration. 2020;99(2):108-118. doi: 10.1159/000504630. Epub 2020 Jan 24.

Abstract

Background: Idiopathic pulmonary fibrosis (IPF) is a life-threatening interstitial lung disease (ILD). Characterizing health outcomes of IPF patients is challenging due to disease rarity.

Objective: This study aimed to identify the burden of disease in patients newly diagnosed with IPF.

Methods: Patients with ≥1 claim with an IPF diagnosis were identified from a United States healthcare insurer's database (2000-2013). Patients with other known causes of ILD or aged <40 years were excluded. Subgroups were compared based on the 2011 change in International Classification of Diseases, 9th Revision (ICD-9) definition of IPF and occurrence of IPF testing. The prevalence and incidence of preselected health conditions of clinical interest were estimated.

Results: Median age of newly diagnosed patients (n = 7,298) was 62 years (54.0% male). Restricting to patients with IPF diagnostic testing did not substantially affect cohort characteristics, nor did ICD-9 IPF coding change. Mean follow-up was 1.7 years; 16.8% of patients died; and a substantial proportion of patients were censored due to end of health plan enrollment (50.7%) and other causes of ILD (19.6%). The incidence of pulmonary hypertension, lung cancer, and claims-based algorithm proxy for acute respiratory worsening of unknown cause was 22.5, 17.6, and 12.6 per 1,000 person-years, respectively.

Conclusions: Patients with IPF had a high disease burden with a variety of health outcomes observed, including a high rate of mortality. Database censoring due to changes in enrollment or other ILD diagnoses limited follow-up. Altering cohort entry definitions, including IPF testing or ICD-9 IPF coding change, had little impact on cohort baseline characteristics.

Keywords: Algorithms; Database; Idiopathic pulmonary fibrosis; Incidence; Insurance, health.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Anticoagulants
  • Bronchoalveolar Lavage
  • Cohort Studies
  • Databases, Factual
  • Disease Progression
  • Emergency Service, Hospital / statistics & numerical data
  • Female
  • Glucocorticoids / therapeutic use*
  • Health Care Costs*
  • Histamine H2 Antagonists / therapeutic use
  • Hospitalization / statistics & numerical data*
  • Humans
  • Idiopathic Pulmonary Fibrosis / economics
  • Idiopathic Pulmonary Fibrosis / epidemiology
  • Idiopathic Pulmonary Fibrosis / therapy*
  • Incidence
  • Lung Neoplasms / epidemiology
  • Lung Transplantation
  • Male
  • Middle Aged
  • Myocardial Infarction / epidemiology
  • Outcome Assessment, Health Care
  • Oxygen Inhalation Therapy*
  • Platelet Aggregation Inhibitors
  • Prevalence
  • Proton Pump Inhibitors / therapeutic use
  • Pulmonary Arterial Hypertension / epidemiology
  • United States / epidemiology

Substances

  • Anticoagulants
  • Glucocorticoids
  • Histamine H2 Antagonists
  • Platelet Aggregation Inhibitors
  • Proton Pump Inhibitors